XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
Subscribe To Our Newsletter & Stay Updated
